NO20005223L - Composition and treatment of inflammatory bowel disease by administration of N-acetylglucosamine in the colon - Google Patents
Composition and treatment of inflammatory bowel disease by administration of N-acetylglucosamine in the colonInfo
- Publication number
- NO20005223L NO20005223L NO20005223A NO20005223A NO20005223L NO 20005223 L NO20005223 L NO 20005223L NO 20005223 A NO20005223 A NO 20005223A NO 20005223 A NO20005223 A NO 20005223A NO 20005223 L NO20005223 L NO 20005223L
- Authority
- NO
- Norway
- Prior art keywords
- inflammatory bowel
- bowel disease
- composition
- acetylglucosamine
- colon
- Prior art date
Links
- 208000022559 Inflammatory bowel disease Diseases 0.000 title abstract 8
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 title abstract 4
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 title abstract 4
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 title abstract 4
- 229950006780 n-acetylglucosamine Drugs 0.000 title abstract 4
- 210000001072 colon Anatomy 0.000 title abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Oppfinnelsen angår en ny sammensetning og en ny fremgangsmåte til å behandle inflammatorisk tarmsykdom (IBD). Mer spesielt angår denne oppfinnelsen en ny sammensetning som inneholder N-acetylglukosamin (NAG) som et aktivt IBD- behandlende middel og en farmasøytisk egnet bærer, og en fremgangsmåte til å administrere sammensetningen til colon for å behandle IBD hos en person som lider av IBD. En sammensetning for å behandle inflammatorisk tarmsykdom hos en pasient som lider av inflammatorisk tarmsykdom omfatter: (a) en terapeutisk mengde av N- acetylglukosamin; og (b) en farmasøytisk akseptabel bærer, tilpasset til å bli administrert til colon hos nevnte pasient.This invention relates to a novel composition and method for treating inflammatory bowel disease (IBD). More particularly, this invention relates to a novel composition containing N-acetylglucosamine (NAG) as an active IBD-treating agent and a pharmaceutically suitable carrier, and to a method of administering the composition to the colon to treat IBD in a person suffering from IBD. A composition for treating inflammatory bowel disease in a patient suffering from inflammatory bowel disease comprises: (a) a therapeutic amount of N-acetylglucosamine; and (b) a pharmaceutically acceptable carrier adapted to be administered to the colon of said patient.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA002234936A CA2234936C (en) | 1998-04-17 | 1998-04-17 | Composition for and treatment of inflammatory bowel disease by colon administration of n-acetylglucosamine |
| PCT/CA1999/000218 WO1999053929A1 (en) | 1998-04-17 | 1999-03-12 | Composition for and treatment of inflammatory bowel disease by colon administration of n-acetylglucosamine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20005223D0 NO20005223D0 (en) | 2000-10-17 |
| NO20005223L true NO20005223L (en) | 2000-11-20 |
Family
ID=4162337
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20005223A NO20005223L (en) | 1998-04-17 | 2000-10-17 | Composition and treatment of inflammatory bowel disease by administration of N-acetylglucosamine in the colon |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP1071432A1 (en) |
| JP (1) | JP2002512195A (en) |
| CA (1) | CA2234936C (en) |
| CZ (1) | CZ20003846A3 (en) |
| HU (1) | HUP0101514A3 (en) |
| IL (1) | IL139072A0 (en) |
| NO (1) | NO20005223L (en) |
| PL (1) | PL343634A1 (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2552842T3 (en) | 2007-02-19 | 2015-12-02 | Marine Polymer Technologies, Inc. | Hemostatic compositions and therapeutic regimens |
| KR101098581B1 (en) | 2009-01-09 | 2011-12-26 | 서울대학교산학협력단 | Composition for Improving Inflammatory Disorder Using ABH Antigen |
| AU2011239466B2 (en) | 2010-04-15 | 2015-01-22 | Marine Polymer Technologies, Inc. | Anti-bacterial applications of poly -N-acetylglucosamine nanofibers |
| MX356877B (en) | 2011-04-15 | 2018-06-19 | Marine Polymer Tech Inc | Treatment of disease with poly-n-acety glucosamine nanofibers. |
| WO2014142938A1 (en) * | 2013-03-15 | 2014-09-18 | Aihol Corporation | Pharmaceutical formulation containing glycosaminoglycan |
| US9539265B2 (en) | 2013-03-15 | 2017-01-10 | Aihol Corporation | Pharmaceutical formulation containing glycosaminoglycan |
| KR20170086044A (en) * | 2014-11-26 | 2017-07-25 | 에보니크 룀 게엠베하 | Pharmaceutical or nutraceutical composition with resistance against the influence of ethanol |
| KR102104507B1 (en) * | 2019-08-23 | 2020-04-24 | 브릿지바이오테라퓨틱스(주) | Pharmaceutical formulations comprising sodium palmitoyl-l-prolyl-l-prolyl-glycyl-l-tyrosinate and methods for preparing the same |
-
1998
- 1998-04-17 CA CA002234936A patent/CA2234936C/en not_active Expired - Fee Related
-
1999
- 1999-03-12 CZ CZ20003846A patent/CZ20003846A3/en unknown
- 1999-03-12 JP JP2000544333A patent/JP2002512195A/en active Pending
- 1999-03-12 IL IL13907299A patent/IL139072A0/en unknown
- 1999-03-12 PL PL99343634A patent/PL343634A1/en unknown
- 1999-03-12 HU HU0101514A patent/HUP0101514A3/en unknown
- 1999-03-12 EP EP99907220A patent/EP1071432A1/en not_active Withdrawn
-
2000
- 2000-10-17 NO NO20005223A patent/NO20005223L/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2234936A1 (en) | 1999-10-17 |
| HUP0101514A3 (en) | 2003-07-28 |
| CZ20003846A3 (en) | 2002-03-13 |
| HUP0101514A2 (en) | 2001-11-28 |
| JP2002512195A (en) | 2002-04-23 |
| CA2234936C (en) | 2004-06-29 |
| PL343634A1 (en) | 2001-08-27 |
| NO20005223D0 (en) | 2000-10-17 |
| EP1071432A1 (en) | 2001-01-31 |
| IL139072A0 (en) | 2001-11-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2005202257C1 (en) | Azacyclic compounds for use in the treatment of serotonin related diseases | |
| NO20033617D0 (en) | Procedure for the treatment of diabetes mellitus | |
| NO20052348L (en) | Treatment of hemorrhagic shock | |
| MY120279A (en) | Use of a celecoxib composition for fast pain relief | |
| BR0012136A (en) | Highly selective norepinephrine reabsorption inhibitors and methods of using them | |
| TW200510349A (en) | Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor | |
| NO20003051L (en) | Method of administration of AspB28 human insulin | |
| SG148850A1 (en) | Methods of treating vascular disease | |
| NO20044562L (en) | Methods for treating bowel disease | |
| CA2241904A1 (en) | Substituted n-[(aminoiminomethyl or aminomethyl)phenyl]propyl amides | |
| TWI367751B (en) | Pharmaceutical composition comprising rapid-onset selective serotonin reuptake inhibitors for treating sexual dysfunction | |
| DE69733089D1 (en) | Treatment of osteotarthritis by administration of poly-N-acetyl-D-glucosamine | |
| NO20024924L (en) | Use of bradycardial substances in the treatment of myocardial diseases in connection with hypertrophy and new drug combinations | |
| ATE305469T1 (en) | SULFONIC ACID OR SULFONYLAMINO-N-(HETEROARALKYL)-AZAHETEROCYCLYL MIDDLE COMPOUNDS | |
| BR0008443A (en) | Inhibitors of branched-chain amino acid-dependent aminotranspheres and their use in the treatment of diabetic retinopathy | |
| UA99094C2 (en) | Method for the treatment of patients with autoantibody positive disease | |
| DE602005009176D1 (en) | TREATMENT OF T-CELL LYMPHOMIC BY 10-PROPARGYL-10-DEAZAAMINEOPTERIN | |
| BR0201974A (en) | Pharmaceutical composition for treating sleep disorders | |
| TW200503666A (en) | Treatment of type 1 diabetes with pde5 inhibitors | |
| CA2234936A1 (en) | Composition for and treatment of inflammatory bowel disease by colon administration of n-acetylglucosamine | |
| NO20055390L (en) | Thorium-227 for use in radiotherapy in soft tissue diseases | |
| NO984974L (en) | Means that improve pulmonary circulation | |
| EP1447090B8 (en) | Use of hyaluronidase for preventing and treating cardiovascular diseases | |
| WO2003024394A3 (en) | Method of treating benign prostatic hyperplasia and other beingn porstate conditions | |
| UA38056A (en) | Method for prediction and control of effectiveness of treatment of hypertension disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |